Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease

Last updated: May 13, 2025
Sponsor: Fred Hutchinson Cancer Center
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Survey Administration

Fecal Microbiota Transplantation

Colonoscopy

Clinical Study ID

NCT05067595
RG1006202
10276
1R01HL166107
NCI-2019-07698
  • Ages > 18
  • All Genders

Study Summary

This phase I trial studies how well fecal microbiota transplant and dietary fiber supplementation work in treating patients with gut graft versus host disease. Fecal microbiota transplant entails inoculating donor stool into a recipient's gastrointestinal tract. Changing the gut microbiome by fecal microbiota transplant and fiber supplementation may help treat gut graft versus host disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years of age or older

  • History of allogeneic hematopoietic stem cell transplant in the past 365 days

  • Post-engraftment, defined by time period following three consecutive days ofsustained neutrophil engraftment with an absolute neutrophil count of at least 500cells/mm^1

  • Mild to severe acute GI GvHD, at least stage 1, as measured by one of the following:

  • Modified Glucksberg criteria for GI GvHD averaged over 3 consecutive days andwithout another explanation for diarrhea such as laxative use or infection. Inpatients who have already had GI biopsy, biopsy histology must be compatiblewith GVHD, although biopsy is not required

  • Biopsy evidence of GI GVHD in the upper or lower GI tract

Exclusion

Exclusion Criteria:

  • History of previous serious adverse events associated with FMT

  • History of bowel perforation in the last 90 days

  • History of gastrointestinal resection in the last 90 days

  • History of intestinal obstruction in the last 90 days

  • History of diverticulitis in the last 90 days

  • History of celiac disease confirmed by serologic testing or small bowel biopsy

  • History of severe dietary allergy as designated by World Allergy OrganizationSubcutaneous Immunotherapy Systemic Reaction Grading System grade 2 or more

  • Subjects who are cytomegalovirus (CMV) seronegative at the time of enrollment asindicated by clinical testing unless the fecal microbiota transplant (FMT) donor isCMV seronegative with negative plasma polymerase chain reaction (PCR) assays forCMV.

  • Known allergies to loperamide, sodium chloride, glycerol, theobroma oil, hide bovinegelatin, sodium lauryl sulfate, colorants FD&C, titanium dioxide, polyethyleneglycol, sodium sulfate, sodium bicarbonate, sodium phosphate, benzalkonium chloride,disodium EDTA or potassium chloride.

  • Currently pregnant, planning to become pregnant or breastfeeding during the studyperiod. Women of childbearing potential (those who are not post-menopausal orpost-hysterectomy) must be negative for pregnancy per urine pregnancy test atenrollment

  • Individuals with the ability to conceive children who are not willing to abstainfrom sexual activity or use an effective form of birth control during the durationof the study

  • Unwilling or unable to participate in study procedures including oral intake of FMT,colonoscopy, fiber supplementation, collection of stool samples and completion studysurveys

  • Cannot reasonably and safely participate in the study in the opinion of theinvestigators

Study Design

Total Participants: 72
Treatment Group(s): 5
Primary Treatment: Survey Administration
Phase: 1
Study Start date:
January 24, 2025
Estimated Completion Date:
December 31, 2026

Study Description

OUTLINE: Patients are randomized to 1 of 4 arms.

ARM I: Patients receive upper FMT capsules orally (PO) over 5 days or via post-pyloric or nasogastric (NG) feeding tube over 2 days.

ARM II: Patients undergo lower FMT via colonoscopy on day 0.

ARM III: Patients receive upper FMT capsules PO over 5 days or via post-pyloric or NG feeding tube over 2 days. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from the first day of FMT administration and up to 6 weeks post FMT.

ARM IV: Patients undergo lower FMT via colonoscopy on day 0. Patients also receive fiber supplementation PO or via post-pyloric or NG feeding tube from day 0 up to 6 weeks post FMT.

Patients also undergo tissue, stool, stool swabs, and blood sample collection throughout the study.

After completion of study treatment, patients are followed up for 365 days.

Connect with a study center

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington 98109
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.